Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Paolo Lissoni

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Disorders

Procedures

Anatomy

Pineal Gland

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
160
Tancini, Gabriele
154
Barni, S
90
Rovelli, Franco
78
Brivio, Fernando
70
Ardizzoia, Antonio
50
Fumagalli, Luca
41
Paolorossi, F
30
Gardani, Gianstefano
23
Giani, Luisa
23
Malugani, Fabio
19
Meregalli, S
16
Vaghi, MM
15
Messina, Giusy
13
Mandalà, Mario
13
Bucovec, R

Sign-in to see all Coauthors

Publications

TOP 3
Lissoni P; Brivio F; Fumagalli L; Messina G; Meregalli S; Porro G; Rovelli F; Vigorè L; Tisi E; D'Amico G
Effects of the conventional antitumor therapies surgery, chemotherapy, radiotherapy and immunotherapy on regulatory T lymphocytes in cancer patients.
Cerrone R; Giani L; Galbiati B; Messina G; Casiraghi M; Proserpio E; Meregalli M; Trabattoni P; Lissoni P; Gardani G
Efficacy of HT 7 point acupressure stimulation in the treatment of insomnia in cancer patients and in patients suffering from disorders other than cancer.
Lissoni P; Messina G; Parolini D; Balestra A; Brivio F; Fumagalli L; Vigore L; Rovelli F
A spiritual approach in the treatment of cancer: relation between faith score and response to chemotherapy in advanced non-small cell lung cancer patients.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Paolo Lissoni (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Lissoni P; Brivio F; Fumagalli L; Messina G; Meregalli S; Porro G; Rovelli F; Vigorè L; Tisi E; D'Amico G
Effects of the conventional antitumor therapies surgery, chemotherapy, radiotherapy and immunotherapy on regulatory T lymphocytes in cancer patients.
Anticancer research 2009;29(5):1847-52.
2008: Cerrone R; Giani L; Galbiati B; Messina G; Casiraghi M; Proserpio E; Meregalli M; Trabattoni P; Lissoni P; Gardani G
Efficacy of HT 7 point acupressure stimulation in the treatment of insomnia in cancer patients and in patients suffering from disorders other than cancer.
Minerva medica 2008;99(6):535-7.
2008: Lissoni P; Messina G; Parolini D; Balestra A; Brivio F; Fumagalli L; Vigore L; Rovelli F
A spiritual approach in the treatment of cancer: relation between faith score and response to chemotherapy in advanced non-small cell lung cancer patients.
In vivo (Athens, Greece) 2008;22(5):577-81.
2008: Lissoni P; Rovelli F; Brivio F; Fumagalli L; Brera G
A study of immunoendocrine strategies with pineal indoles and interleukin-2 to prevent radiotherapy-induced lymphocytopenia in cancer patients.
In vivo (Athens, Greece) 2008;22(3):397-400.
2008: Lissoni Paolo; Brivio Fernando; Fumagalli Luca; Messina Giusy; Vigoré Luigi; Parolini Daniela; Colciago Massimo; Rovelli Franco
Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors.
Anticancer research 2008;28(2B):1377-81.
2007: Gardani G; Cerrone R; Biella C; Galbiati G; Proserpio E; Casiraghi M; Arnoffi J; Meregalli M; Trabattoni P; Dapretto E; Giani L; Messina G; Lissoni P
A progress study of 100 cancer patients treated by acupressure for chemotherapy-induced vomiting after failure with the pharmacological approach.
Minerva medica 2007;98(6):665-8.
2007: Gardani G; Cerrone R; Biella C; Galbiati B; Proserpio E; Casiraghi M; Travisi O; Meregalli M; Trabattoni P; Colombo L; Giani L; Messina G; Arnoffi J; Lissoni P
A case-control study of Panicum Miliaceum in the treatment of cancer chemotherapy-induced alopecia.
Minerva medica 2007;98(6):661-4.
2007: Lissoni P; Brivio F; Fumagalli L; Messina G; Secreto G; Romelli B; Fumagalli G; Rovelli F; Colciago M; Brera G
Immune and endocrine mechanisms of advanced cancer-related hypercortisolemia.
In vivo (Athens, Greece) 2007;21(4):647-50.
2007: Messina G; Lissoni P; Bartolacelli E; Fumagalli L; Brivio F; Colombo E; Gardani G S
Efficacy of IL-2 immunotherapy in metastatic renal cell carcinoma in relation to the psychic profile as evaluated using the Rorschach test.
Anticancer research 2007;27(4C):2985-8.
2006: Gardani G; Cerrone R; Biella C; Mancini L; Proserpio E; Casiraghi M; Travisi O; Meregalli M; Trabattoni P; Colombo L; Giani L; Vaghi M; Lissoni P
Effect of acupressure on nausea and vomiting induced by chemotherapy in cancer patients.
Minerva medica 2006;97(5):391-4.
2006: Lissoni P; Fumagalli L; Brivio F; Rovelli F; Messina G; Di Fede G; Colciago M; Brera G
Cancer chemotherapy-induced lymphocytosis: a revolutionary discovery in the medical oncology.
Journal of biological regulators and homeostatic agents 2006;20(1-2):29-35.
2006: Brivio Fernando; Fumagalli Luca; Lissoni Paolo; Nardone Armando; Nespoli Luca; Fattori Luca; Denova Marianna; Chiarelli Marco; Nespoli Angelo
Pre-operative immunoprophylaxis with interleukin-2 may improve prognosis in radical surgery for colorectal cancer stage B-C.
Anticancer research 2006;26(1B):599-603.
2006: Lissoni P; Viganò P; Podraska A; Brivio R; Colciago M; Casu M; Manganini V; Giuberti C; Strada G; Gardani G
Chromogranin A blood concentrations in relation to those of prolactin in hormone-refractory metastatic prostate cancer: possible existence of two independent mechanisms responsible for endocrine resistance.
The International journal of biological markers 2006;21(1):58-9.
2005: Lissoni P; Brivio F; Fumagalli L; Di Fede G; Brera G
Enhancement of the efficacy of chemotherapy with oxaliplatin plus 5-fluorouracil by pretreatment with IL-2 subcutaneous immunotherapy in metastatic colorectal cancer patients with lymphocytopenia prior to therapy.
In vivo (Athens, Greece) 2005;19(6):1077-80.
2005: Lissoni P; Vigano P; Vaghi M; Frontini L; Giuberti C; Manganini V; Casu M; Brivio F; Niespolo R; Strada G
A phase II study of tamoxifen in hormone-resistant metastatic prostate cancer: possible relation with prolactin secretion.
Anticancer research 2005;25(5):3597-9.
2005: Lissoni P; Meregalli S; Bonetto E; Mancuso M; Brivio F; Colciago M; Gardani G
Radiotherapy-induced lymphocytopenia: changes in total lymphocyte count and in lymphocyte subpopulations under pelvic irradiation in gynecologic neoplasms.
Journal of biological regulators and homeostatic agents 2005;19(3-4):153-8.
2005: Lissoni P; Messina G; Brivio F; Rovelli F; Di Fede G; Mainini E; Veronese E
Cortisol response to an acute injection of IL-2 in healthy subjects and cancer patients: a first immunoneuroendocrine standardized clinical test to explore the interactions between immune and neuroendocrine systems.
Journal of biological regulators and homeostatic agents 2005;19(3-4):141-4.
2005: Lissoni P; Bignami A; Frontini L; Manganini V; Dapretto E; Gardani G S; Viganò P; Strada G
Possible involvement of prolactin in endocrine-resistant metastatic prostate cancer.
The International journal of biological markers 2005;20(2):123-5.
2005: Bignami A; Lissoni P; Brivio F; Galbiati F; Pescia S; Messina G; Frontini L; Meregalli S; Gardani G S
The favorable prognostic significance of surgery-induced hyperprolactinemia in node-positive breast cancer patients: ten-year disease-free survival results.
The International journal of biological markers 2005;20(1):60-4.
2004: Frontini L; Lissoni P; Vaghi M; Perego M S; Pescia S; Ardizzoia A; Gardani G
Enhancement of the efficacy of weekly low-dose taxotere by the long acting anti-prolactinemic drug cabergoline in pretreated metastatic breast cancer.
Anticancer research 2004;24(6):4223-6.
2004: Lissoni Paolo; Perego Maristella; Veronese Elisabetta; Fumagalli Gabriele; Brivio Fernando; Colciago Massimo; Messina Giusy; Rovelli Franco; Brivio Rinaldo; Gardani Gianstefano
Endocrine effects of erythropoietin in cancer patients.
Hematology (Amsterdam, Netherlands) 2004;9(5-6):363-7.
2004: Lissoni P; Vaghi M; Pescia S; Rovelli F; Ardizzola A; Valtulina F; Malugani F; Gardani G; Tancini G
Biological response modifiers of cancer-related neuroendocrine disorders: efficacy of the long-term dopaminergic agonist cabergoline in the treatment of breast cancer-induced hyperprolactinemia.
Journal of biological regulators and homeostatic agents 2004;18(3-4):291-4.
2004: Lissoni P; Brivio F; Fumagalli L; Messina G; Ghezzi V; Frontini L; Giani L; Vaghi M; Ardizzoia A; Gardani G S
Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors.
The International journal of biological markers 2004;19(2):135-40.
2003: Lissoni P; Messina G; Vaghi M; Bartolacelli E; Massarenti L L; Trabattoni P; Meregalli P; Meregalli M; Gavazzeni C; Rovelli F; Tancini G; Gardani G S
A psychoneuroendocrine study of brain dopaminergic sensitivity in locally limited or metastatic cancer patients.
In vivo (Athens, Greece) 2003;17(6):647-50.
2003: Messina G; Lissoni P; Bartolacelli E; Tancini G; Villa S; Gardani G S; Brivio F
A psychoncological study of lymphocyte subpopulations in relation to pleasure-related neurobiochemistry and sexual and spiritual profile to Rorschach's test in early or advanced cancer patients.
Journal of biological regulators and homeostatic agents 2003;17(4):322-6.
2003: Lissoni P; Chilelli M; Villa S; Cerizza L; Tancini G
Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial.
Journal of pineal research 2003;35(1):12-5.
2003: Lissoni Paolo; Malugani Fabio; Brivio Fernando; Piazza Alessandra; Vintimilla Carmen; Giani Luisa; Tancini Gabriele
Total pineal endocrine substitution therapy (TPEST) as a new neuroendocrine palliative treatment of untreatable metastatic solid tumor patients: a phase II study.
Neuro endocrinology letters 2003;24(3-4):259-62.
2003: Cerea G; Vaghi M; Ardizzoia A; Villa S; Bucovec R; Mengo S; Gardani G; Tancini G; Lissoni P
Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations.
Anticancer research 2003;23(2C):1951-4.
2003: Lissoni Paolo; Malugani Fabio; Bukovec Roberta; Bordin Veronica; Perego Maristella; Mengo Susan; Ardizzoia Antonio; Tancini Gabriele
Reduction of cisplatin-induced anemia by the pineal indole 5-methoxytryptamine in metastatic lung cancer patients.
Neuro endocrinology letters 2003;24(1-2):83-5.
2003: Lissoni Paolo; Malugani Fabio; Manganini Vittorio; Ardizzoia Antonio; Gardani Gianstefano; Bartolacelli Erio; Messina Giusy; Tancini Gabriele
Psychooncology and cancer progression-related alterations of pleasure-associated neurochemical system: Abnormal neuroendocrine response to apomorphine in advanced cancer patients.
Neuro endocrinology letters 2003;24(1-2):50-3.
2003: Lissoni P; Vaghi M; Villa S; Bodraska A; Cerizza L; Tancini G; Gardani G S
Antiprolactinemic approach in the treatment of metastatic breast cancer: a phase II study of polyneuroendocrine therapy with LHRH-analogue, tamoxifen and the long-acting antiprolactinemic drug cabergoline.
Anticancer research 2003;23(1B):733-6.
2003: Lissoni P; Mengo S; Bucovec R; Brivio F; Fumagalli L; Tancini G; Gardani G S
Clinical and biological effects of interleukin-2 with or without a concomitant administration of granulocyte-macrophage colony-stimulating factor in metastatic cancer patients.
In vivo (Athens, Greece) 2003;17(1):73-5.
2002: Lissoni Paolo; Malugani Fabio; Malysheva Ola; Kozlov Vladimir; Laudon Moshe; Conti Ario; Maestroni Georges
Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system.
Neuro endocrinology letters 2002;23(4):341-4.
2002: Lissoni Paolo; Malugani Fabio; Bordin Veronica; Conti Ario; Maestroni George; Tancini Gabriele
A new neuroimmunotherapeutic strategy of subcutaneous low-dose interleukin-2 plus the long-acting opioid antagonist naltrexone in metastatic cancer patients progressing on interleukin-2 alone.
Neuro endocrinology letters 2002;23(3):255-8.
2002: Lissoni P; Bucovec R; Malugani F; Ardizzoia A; Villa S; Gardani G S; Vaghi M; Tancini G
A clinical study of taxotere versus taxotere plus the antiprolactinemic agent bromocriptine in metastatic breast cancer pretreated with anthracyclines.
Anticancer research 2002;22(2B):1131-4.
2002: Lissoni P; Bordin V; Vaghi M; Fumagalli L; Bordoni A; Mengo S; Bucovec R; Fumagalli E; Malugani F; Ardizzoia A; Giani L; Gardani G S; Tancini G
Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2.
Anticancer research 2002;22(2B):1061-4.
2002: Lissoni P; Vaghi M; Ardizzoia A; Malugani F; Fumagalli E; Bordin V; Fumagalli L; Bordoni A; Mengo S; Gardani G S; Tancini G
A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
In vivo (Athens, Greece) 2002;16(2):93-6.
2002: Brivio Fernando; Lissoni Paolo; Rovelli Franco; Nespoli Angelo; Uggeri Franco; Fumagalli Luca; Gardani Gianstefano
Effects of IL-2 preoperative immunotherapy on surgery-induced changes in angiogenic regulation and its prevention of VEGF increase and IL-12 decline.
Hepato-gastroenterology 2002;49(44):385-7.
2002: Lissoni P
Is there a role for melatonin in supportive care?
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2002;10(2):110-6.
2002: Lissoni Paolo; Malugani Fabio; Casu Marilena; Bukovec Roberta; Egardi Remo; Bordin Veronica; Fumagalli Elena; Mengo Susan; Gardani Gianstefano
Effect of bicalutamide therapy on prolactin response to L-dopa in metastatic prostate cancer patients.
Neuro endocrinology letters 2002;23(1):61-3.
2001: Brivio F; Lissoni P; Perego M S; Lissoni A; Fumagalli L
Abrogation of surgery-induced IL-6 hypersecretion by presurgical immunotherapy with IL-2 and its importance in the prevention of postoperative complications.
Journal of biological regulators and homeostatic agents 2001;15(4):370-4.
2001: Lissoni P; Cangemi P; Pirato D; Roselli M G; Rovelli F; Brivio F; Malugani F; Maestroni G J; Conti A; Laudon M; Malysheva O; Giani L
A review on cancer--psychospiritual status interactions.
Neuro endocrinology letters 2001;22(3):175-80.
2001: Lissoni P; Fumagalli E; Malugani F; Ardizzoia A; Bucovec R; Tancini G; Gardani G S
Stimulation of IL-12 secretion by GM-CSF in advanced cancer patients.
Journal of biological regulators and homeostatic agents 2001;15(2):163-5.
2001: Lissoni P; Malugani F; Bonfanti A; Bucovec R; Secondino S; Brivio F; Ferrari-Bravo A; Ferrante R; Vigoré L; Rovelli F; Mandalà M; Viviani S; Fumagalli L; Gardani G S
Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1.
Journal of biological regulators and homeostatic agents 2001;15(2):140-4.
2001: Lissoni P; Rovelli F; Vellani D; Malugani F; Bucovec R; Chapovalenko L; Fumagalli E; Gardani G
Stimulation of IL-18 secretion by IL-2 in patients with advanced cancer.
The International journal of biological markers 2001;16(2):146-7.
2001: Viganò D; Lissoni P; Rovelli F; Roselli M G; Malugani F; Gavazzeni C; Conti A; Maestroni G
A study of light/dark rhythm of melatonin in relation to cortisol and prolactin secretion in schizophrenia.
Neuro endocrinology letters 2001;22(2):137-41.
2001: Lissoni P; Bucovec R; Bonfanti A; Giani L; Mandelli A; Roselli M G; Rovelli F; Fumagalli L
Thrombopoietic properties of 5-methoxytryptamine plus melatonin versus melatonin alone in the treatment of cancer-related thrombocytopenia.
Journal of pineal research 2001;30(2):123-6.
2001: Lissoni P; Rovelli F; Baiocco N; Tangini G; Fumagalli L
A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone.
Anticancer research 2001;21(1B):777-9.
2001: Lissoni P; Rovelli F; Malugani F; Bucovec R; Conti A; Maestroni G J
Anti-angiogenic activity of melatonin in advanced cancer patients.
Neuro endocrinology letters 2001;22(1):45-7.
2001: Lissoni P; Vaghi M; Ardizzoia A; Fumagalli E; Tancini G; Gardani G; Conti A; Maestroni G J
Efficacy of monochemotherapy with docetaxel (taxotere) in relation to prolactin secretion in heavily pretreated metastatic breast cancer.
Neuro endocrinology letters 2001;22(1):27-9.
2000: Lissoni P; Brivio F; Rovelli F; Fumagalli G; Malugani F; Vaghi M; Secondino S; Bucovec R; Gardani G S
Serum concentrations of interleukin-18 in early and advanced cancer patients: enhanced secretion in metastatic disease.
Journal of biological regulators and homeostatic agents 2000;14(4):275-7.
2000: Lissoni P; Fugamalli E; Malugani F; Ardizzoia A; Secondino S; Tancini G; Gardani G S
Chemotherapy and angiogenesis in advanced cancer: vascular endothelial growth factor (VEGF) decline as predictor of disease control during taxol therapy in metastatic breast cancer.
The International journal of biological markers 2000;15(4):308-11.
2000: Brivio F; Gilardi R; Bucocev R; Ferrante R; Rescaldani R; Vigoré L; Fumagalli L; Nespoli A; Lissoni P
Surgery-induced decline in circulating dendritic cells in operable cancer patients: a possible explanation of postoperative immunosuppression.
Hepato-gastroenterology 2000;47(35):1337-9.
2000: Brivio F; Lissoni P; Gilardi R; Ferrante R; Vigore L; Curzi L; Uggeri F; Nespoli A; Fumagalli L
Abrogation of surgery-induced decline in circulating dendritic cells by subcutaneous preoperative administration of IL-2 in operable cancer patients.
Journal of biological regulators and homeostatic agents 2000;14(3):200-3.
2000: Lissoni P; Mandalà M; Brivio F
Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatonin.
European urology 2000;38(1):115-8.
2000: Lissoni P; Bolis S; Brivio F; Fumagalli L
A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies.
Anticancer research 2000;20(3B):2103-5.
2000: Lissoni P; Mandalà M; Rovelli F; Casu M; Rocco F; Tancini G; Scardino E
Paradoxical stimulation of prolactin secretion by L-dopa in metastatic prostate cancer and its possible role in prostate-cancer-related hyperprolactinemia.
European urology 2000;37(5):569-72.
2000: Bonfanti A; Lissoni P; Bucovec R; Rovelli F; Brivio F; Fumagalli L
Changes in circulating dendritic cells and IL-12 in relation to the angiogenic factor VEGF during IL-2 immunotherapy of metastatic renal cell cancer.
The International journal of biological markers 2000;15(2):161-4.
2000: Ferrari-Bravo A; Franciosi C; Lissoni P; Fumagalli L; Uggeri F
Effects of oncological surgery on endothelin-1 secretion in patients with operable gastric cancer.
The International journal of biological markers 2000;15(1):56-7.
2000: Lissoni P; Brivio F; Ferrante R; Vigore L; Vaghi M; Fumagalli E; Bucovec R; Malugani F; Fumagalli L
Circulating immature and mature dendritic cells in relation to lymphocyte subsets in patients with gastrointestinal tract cancer.
The International journal of biological markers 2000;15(1):22-5.
2000: Lissoni P
Modulation of anticancer cytokines IL-2 and IL-12 by melatonin and the other pineal indoles 5-methoxytryptamine and 5-methoxytryptophol in the treatment of human neoplasms.
Annals of the New York Academy of Sciences 2000;917():560-7.
2000: Bordin V; Giani L; Meregalli S; Bukovec R; Vaghi M M; Mandalà M; Paolorossi F; Ardizzoia A; Tancini G; Barni S; Frigerio F; Fumagalli L; Bordoni A; Valsuani G; Di Felice G; Lissoni P
Five-year survival results of subcutaneous low-dose immunotherapy with interleukin-2 alone in metastatic renal cell cancer patients.
Urologia internationalis 2000;64(1):3-8.
1999: Mandalà M; Lissoni P; Ardizzoia A; Barni S; Rovelli F; Confalonieri G; Malugani F; Moro C; Fumagalli G; Giani L; Tancini G
Endocrinological study of the dopaminergic regulation of prolactin release in metastatic breast cancer.
Tumori 1999;85(6):494-7.
1999: Lissoni P; Barni S; Mandalà M; Ardizzoia A; Paolorossi F; Vaghi M; Longarini R; Malugani F; Tancini G
Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status.
European journal of cancer (Oxford, England : 1990) 1999;35(12):1688-92.
1999: Brivio F; Lissoni P; Fumagalli L; Girlando M; Marsili M T; Nespoli A; Uggeri F
Pre-operative IL-2 immunoprophylaxis of cancer recurrence: long-term clinical results of a phase II study in radically operable colorectal cancer.
Oncology reports 1999;6(6):1205-7.
1999: Lissoni P; Vigore L; Ferranti R; Bukovec R; Meregalli S; Mandala M; Barni S; Tancini G; Fumagalli L; Giani L
Circulating dendritic cells in early and advanced cancer patients: diminished percent in the metastatic disease.
Journal of biological regulators and homeostatic agents 1999;13(4):216-9.
1999: Lissoni P; Bucovec R; Meregalli S; Fumagalli L; Vigorè L; Ferrante R; Brivio F
IL-2 immunotherapy-induced increase in IL-12 blood concentrations may depend on an increase in circulating dendritic cell number.
The International journal of biological markers 1999;14(3):195-7.
1999: Lissoni P; Bolis S; Mandalà M; Viviani S; Pogliani E; Barni S
Blood concentrations of tumor necrosis factor-alpha in malignant lymphomas and their decrease as a predictor of disease control in response to low-dose subcutaneous immunotherapy with interleukin-2.
The International journal of biological markers 1999;14(3):167-71.
1999: Fumagalli L; Lissoni P; Di Felice G; Meregalli S; Valsuani G; Mengo S; Rovelli F
Pretreatment serum markers and lymphocyte response to interleukin-2 therapy.
British journal of cancer 1999;80(3-4):407-11.
1999: Lissoni P; Brivio F; Viviani S; Fumagalli L
Which immunological parameters are clinically essential to monitor IL-2 cancer immunotherapy?
Journal of biological regulators and homeostatic agents 1999;13(2):110-4.
1999: Lissoni P; Fumagalli L; Paolorossi F; Mandalà M
Changes in lymphocyte number during cancer chemotherapy and their relation to clinical response.
The International journal of biological markers 1999;14(2):115-7.
1999: Lissoni P; Tancini G; Paolorossi F; Mandalà M; Ardizzoia A; Malugani F; Giani L; Barni S
Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin: a phase II study.
Journal of pineal research 1999;26(3):169-73.
1999: Lissoni P; Rovelli F; Pittalis S; Casati M; Giani L; Barni S; Fumagalli L; Laudon M
[Therapy with melatonin does not suppress its endogenous production in healthy volunteers]
Recenti progressi in medicina 1999;90(2):84-5.
1998: Lissoni P; Rovelli F; Mandalà M; Barni S
Blood concentrations of interleukin-15 in cancer patients and their variations during interleukin-2 immunotherapy: preliminary considerations.
The International journal of biological markers 1998;13(3):169-71.
1998: Lissoni P; Rovelli F; Giani L; Mandala M; Meregalli S; Barni S; Confalonieri G; Bonfanti A
Dehydroepiandrosterone sulfate (DHEAS) secretion in early and advanced solid neoplasms: selective deficiency in metastatic disease.
The International journal of biological markers 1998;13(3):154-7.
1998: Lissoni P; Rovelli F; Fumagalli G; Confalonieri G; Brivio F; Mariani M
[Pharmacokinetics of melatonin]
Recenti progressi in medicina 1998;89(7-8):381-2.
1998: Lissoni P; Fumagalli L; Rovelli F; Brivio F; Di Felice G; Majorca F
In vivo stimulation of IL-12 secretion by subcutaneous low-dose IL-2 in metastatic cancer patients.
British journal of cancer 1998;77(11):1957-60.
1998: Lissoni P; Fumagalli L; Giani L; Rovelli F; Confalonieri G; Pescia S
Vascular endothelial growth factor (VEGF) serum levels during cancer immunotherapy with IL-2: preliminary considerations.
The International journal of biological markers 1998;13(2):98-101.
1998: Lissoni P; Rovelli F; Giani L; Gavazzeni C; Grazia Roselli M; Mainini E; Mazzi C
Endocrine effects of two pineal hormones other than melatonin in healthy volunteers: 5-methoxytryptophol and 5-methoxytryptamine.
Recenti progressi in medicina 1998;89(4):183-5.
1998: Lissoni P; Mengo S; Mandalà M; Mauri E; Brivio F; Rovelli F; Confalonieri G; Longarini R; Bonfante A; Folli D; Meregalli S; Barni S; Tancini G; Giani L
Physiopathology of IL-12 in human solid neoplasms: blood levels of IL-12 in early or advanced cancer patients, and their variations with surgery and immunotherapy.
Journal of biological regulators and homeostatic agents 1998;12(1-2):38-41.
1998: Barni S; Lissoni P; Meregalli S; Ardizzoia A; Mengo S; Musco F; Merlini D; Tancini G
Clinical efficacy of the aromatase inhibitor anastrozole in relation to prolactin secretion in heavily pretreated metastatic breast cancer.
Tumori 1998;84(1):45-7.
1998: Lissoni P; Rovelli F; Giani L; Fumagalli L; Mandalà M
Immunomodulatory effects of IL-12 in relation to the pineal endocrine function in metastatic cancer patients.
Natural immunity 1998;16(5-6):178-84.
1998: Lissoni P; Giani L; Zerbini S; Trabattoni P; Rovelli F
Biotherapy with the pineal immunomodulating hormone melatonin versus melatonin plus aloe vera in untreatable advanced solid neoplasms.
Natural immunity 1998;16(1):27-33.
1998: Lissoni P; Rovelli F; Brivio F; Brivio O; Fumagalli L
Circadian secretions of IL-2, IL-12, IL-6 and IL-10 in relation to the light/dark rhythm of the pineal hormone melatonin in healthy humans.
Natural immunity 1998;16(1):1-5.
1997: Lissoni P
Effects of low-dose recombinant interleukin-2 in human malignancies.
The cancer journal from Scientific American 1997;3 Suppl 1():S115-20.
1997: Lissoni P; Rovelli F; Meregalli S; Fumagalli L; Musco F; Brivio F; Brivio O; Esposti G
Melatonin as a new possible anti-inflammatory agent.
Journal of biological regulators and homeostatic agents 1997;11(4):157-9.
1997: Lissoni P; Rovelli F; Rivolta M R; Frigerio C; Mandalà M; Barni S; Ardizzoia A; Malugani F; Tancini G
Acute endocrine effects of interleukin-12 in cancer patients.
Journal of biological regulators and homeostatic agents 1997;11(4):154-6.
1997: Lissoni P; Rovelli F; Pittalis S; Casati M; Perego M S; Grassi M G; Brivio F; Fumagalli L
Interleukin-12 in early or advanced cancer patients.
European journal of cancer (Oxford, England : 1990) 1997;33(10):1703-5.
1997: Pittalis S; Lissoni P; Giani L; Casati M; Kropacek N; Orfanò S; Giavolucci F; Merlini D
Effect of a chronic therapy with the pineal hormone melatonin on cholesterol levels in idiopathic hypercholesterolemic patients.
Recenti progressi in medicina 1997;88(9):401-2.
1997: Lissoni P; Paolorossi F; Ardizzoia A; Barni S; Chilelli M; Mancuso M; Tancini G; Conti A; Maestroni G J
A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state.
Journal of pineal research 1997;23(1):15-9.
1997: Lissoni P; Fumagalli L; Paolorossi F; Rovelli F; Roselli M G; Maestroni G J
Anticancer neuroimmunomodulation by pineal hormones other than melatonin: preliminary phase II study of the pineal indole 5-methoxytryptophol in association with low-dose IL-2 and melatonin.
Journal of biological regulators and homeostatic agents 1997;11(3):119-22.
1997: Lissoni P; Barni S; Di Felice G; Majorca F; Fumagalli L
Neopterin, soluble IL-2 receptor and IL-6 secretion during IL-2 cancer immunotherapy: prognostic significance in relation to IL-12 variations.
The International journal of biological markers 1997;12(3):134-6.
1997: Lissoni P; Rovelli F; Fumagalli L; Mauri E; Barni S; Tancini G
Increased blood concentrations of interleukin-12 are associated with a longer survival in untreatable metastatic solid tumor patients: preliminary observations.
The International journal of biological markers 1997;12(3):125-7.
1997: Lissoni P; Barni S; Ardizzoia A; Paolorossi F; Tancini G; Andres M; Favini P; Scardino E; Rocco F
[Immunotherapy for metastatic renal carcinoma with interleukin-2 in a subcutanous administration schedule of short duration. Subcutaneous IL-2 in renal carcinoma]
Archivio italiano di urologia, andrologia : organo ufficiale [di] Società italiana di ecografia urologica e nefrologica / Associazione ricerche in urologia 1997;69(3):159-62.
1997: Lissoni P; Merlini D; Pirato D; Meregalli S
Interleukin-4 blood concentrations in early and metastatic human solid neoplasms.
The International journal of biological markers 1997;12(2):75-8.
1997: Lissoni P; Tancini G; Barni S; Paolorossi F; Ardizzoia A; Conti A; Maestroni G
Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1997;5(2):126-9.
1997: Scardino E; Lissoni P; Andres M; Frea B; Favini P; Kocjancic E; Verweij F; Barani S; Tancini G; Rocco F
[Preoperative subcutaneous immunotherapy with interleukin-2 in renal carcinoma with synchronous metastasis: randomized clinico-biological study. Preoperative use of Il-2 in renal carcinoma]
Archivio italiano di urologia, andrologia : organo ufficiale [di] Società italiana di ecografia urologica e nefrologica / Associazione ricerche in urologia 1997;69(1):49-54.
1997: Lissoni P; Barni S; Tancini G; Cazzaniga M; Frigerio F; Chilelli M; Scardino E; Andres M; Favini P; Meroni T; Verwei F; Baccalin A; Sala M; Frea B; Kocjancic E; Rocco F
[Clinical response and survival in metastatic renal carcinoma during subcutaneous administration of interleukin-2 alone. Subcutaneous Il-2 in renal carcinoma]
Archivio italiano di urologia, andrologia : organo ufficiale [di] Società italiana di ecografia urologica e nefrologica / Associazione ricerche in urologia 1997;69(1):41-7.
1997: Lissoni P; Cazzaniga M; Barni S; Perego M S; Brivio F; Fumagalli L; Tancini G
Acute effects of pamidronate administration on serum levels of interleukin-6 in advanced solid tumour patients with bone metastases and their possible implications in the immunotherapy of cancer with interleukin-2.
European journal of cancer (Oxford, England : 1990) 1997;33(2):304-6.
1997: Lissoni P; Cazzaniga M; Tancini G; Scardino E; Musci R; Barni S; Maffezzini M; Meroni T; Rocco F; Conti A; Maestroni G
Reversal of clinical resistance to LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin: efficacy of LHRH analogue plus melatonin in patients progressing on LHRH analogue alone.
European urology 1997;31(2):178-81.
1996: Lissoni P; Tancini G; Barni S; Paolorossi F; Rossini F; Maffé P; Di Bella L
The pineal hormone melatonin in hematology and its potential efficacy in the treatment of thrombocytopenia.
Recenti progressi in medicina 1996;87(12):582-5.
1996: Lissoni P; Brivio O; Brivio F; Barni S; Tancini G; Crippa D; Meregalli S
Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma.
Journal of pineal research 1996;21(4):239-42.
1996: Lissoni P; Paolorossi F; Tancini G; Ardizzoia A; Barni S; Brivio F; Maestroni G J; Chilelli M
A phase II study of tamoxifen plus melatonin in metastatic solid tumour patients.
British journal of cancer 1996;74(9):1466-8.
1996: Di Felice G; Fumagalli L; Majorca F; Barni S; Ardizzoia A; Tancini G; Lissoni P
Reactivation of a normal endogenous secretion of interleukin-2 in metastatic cancer patients by a chronic subcutaneous injection of interleukin-2.
Journal of biological regulators and homeostatic agents 1996;10(4):98-9.
1996: Lissoni P; Rovelli F; Giani L; Fumagalli L; Meregalli S; Comi G; Merlini D
Correlation between IL-12 and IL-2 blood levels in the metastatic neoplastic disease: a possible inhibitory feedback system regulating their secretion.
Journal of biological regulators and homeostatic agents 1996;10(4):92-4.
1996: Lissoni P; Paolorossi F; Tancini G; Barni S; Ardizzoia A; Brivio F; Zubelewicz B; Chatikhine V
Is there a role for melatonin in the treatment of neoplastic cachexia?
European journal of cancer (Oxford, England : 1990) 1996;32A(8):1340-3.
1996: Lissoni P; Pittalis S; Ardizzoia A; Brivio F; Barni S; Tancini G; Pelizzoni F; Maestroni G J; Zubelewicz B; Braczkowski R
Prevention of cytokine-induced hypotension in cancer patients by the pineal hormone melatonin.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1996;4(4):313-6.
1996: Brivio F; Lissoni P; Alderi G; Barni S; Lavorato F; Fumagalli L
Preoperative interleukin-2 subcutaneous immunotherapy may prolong the survival time in advanced colorectal cancer patients.
Oncology 1996;53(4):263-8.
1996: Lissoni P; Brivio F; Pittalis S; Rovelli F; Rescaldani R; Perego M S; Grassi M G; Barni S; Tancini G; Majorca F; Fumagalli L
Clinical significance of erythrosedimentation rate in cancer in relation to cytokine production: correlation with high IL-6 and low IL-2 blood concentrations.
Journal of biological regulators and homeostatic agents 1996;10(2-3):60-2.
1996: Lissoni P; Pittalis S; Rovelli F; Zecchini S; Casati M; Tremolada M; Pelizzoni F
Immunomodulatory properties of a pineal indole hormone other than melatonin, the 5-methoxytryptophol.
Journal of biological regulators and homeostatic agents 1996;10(1):27-30.
1996: Lissoni P; Pittalis S; Roselli M G; Rovelli F; Viganò M G
Comparison between interleukin-2 and interleukin-12: effects on monocyte functions and their possible importance in the clinical significance of neopterin.
The International journal of biological markers 1996;11(1):58-9.
1996: Lissoni P; Ardizzoia A; Barni S; Pittalis S; Rossini F; Porta A; Tancini G
Characterization of cancer-related disseminated intravascular coagulation in relation to tumor necrosis factor-alpha blood concentrations: possible therapeutic role of pentoxifylline.
Tumori 1996;82(1):78-80.
1996: Barni S; Lissoni P; Tancini G; Ardizzoia A; Cazzaniga M
Effects of one-year adjuvant treatment with tamoxifen on bone mineral density in postmenopausal breast cancer women.
Tumori 1996;82(1):65-7.
1996: Lissoni P; Meregalli S; Nosetto L; Barni S; Tancini G; Fossati V; Maestroni G
Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone.
Oncology 1996;53(1):43-6.
1995: Lissoni P; Barni S; Cazzaniga M; Ardizzoia A; Rovelli F; Tancini G; Brivio F; Frigerio F
Prediction of recurrence in operable breast cancer by postoperative changes in prolactin secretion.
Oncology 1995;52(6):439-42.
1995: Lissoni P; Vigorè L; Rescaldani R; Rovelli F; Brivio F; Giani L; Barni S; Tancini G; Ardizzoia A; Viganò M G
Neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin in AIDS patients with CD4 cell number below 200/mm3: a biological phase-II study.
Journal of biological regulators and homeostatic agents 1995;9(4):155-8.
1995: Lissoni P; Rovelli F; Tisi E; Brivio F; Ardizzoia A; Barni S; Tancini G; Saudelli M; Cesana E; Viganò M G
Relation between macrophage and T helper-2 lymphocyte functions in human neoplasms: neopterin, interleukin-10 and interleukin-6 blood levels in early or advanced solid tumors.
Journal of biological regulators and homeostatic agents 1995;9(4):146-9.
1995: Braczkowski R; Zubelewicz B; Romanowski W; Lissoni P; Barni S
Modulation of tumor necrosis factor-alpha (TNF-alpha) toxicity by the pineal hormone melatonin (MLT) in metastatic solid tumor patients.
Annals of the New York Academy of Sciences 1995;768():334-6.
1995: Lissoni P; Barni S; Brivio F; Rossini F; Fumagalli L; Ardizzoia A; Tancini G
A biological study on the efficacy of low-dose subcutaneous interleukin-2 plus melatonin in the treatment of cancer-related thrombocytopenia.
Oncology 1995;52(5):360-2.
1995: Zubelewicz B; Braczkowski R; Rovelli F; Lissoni P; Pittalis S
Stimulation of soluble interleukin-2 release by tumor necrosis factor-alpha in cancer patients.
The International journal of biological markers 1995;10(3):186-7.
1995: Lissoni P; Barni S; Ardizzoia A; Frigerio F; Paolorossi F; Cazzaniga M; Tancini G; Rocco F; Aapro M
Clinical efficacy of cancer subcutaneous immunotherapy with interleukin-2 in relation to the pretreatment levels of tumor growth factor insulin-like growth factor-1.
Tumori 1995;81(4):261-4.
1995: Barni S; Lissoni P; Cazzaniga M; Ardizzoia A; Meregalli S; Fossati V; Fumagalli L; Brivio F; Tancini G
A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates.
Oncology 1995;52(3):243-5.
1995: Lissoni P; Barni S; Fossati V; Ardizzoia A; Cazzaniga M; Tancini G; Frigerio F
A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1995;3(3):194-7.
1995: Lissoni P; Pittalis S; Rovelli F; Vigorè L; Roselli M G; Brivio F
Interleukin-2, melatonin and interleukin-12 as a possible neuroimmune combination in the biotherapy of cancer.
Journal of biological regulators and homeostatic agents 1995;9(2):63-6.
1995: Lissoni P; Barni S; Brivio F; Rossini F; Fumagalli L; Tancini G
Treatment of cancer-related thrombocytopenia by low-dose subcutaneous interleukin-2 plus the pineal hormone melatonin: a biological phase II study.
Journal of biological regulators and homeostatic agents 1995;9(2):52-4.
1995: Lissoni P; Scardino E; Favini P; Barni S; Tancini G; Baccalin A; Verweij F; Strada G; Musci R; Rocco F
[Prognostic predictive factors of the clinical response to immunotherapy with subcutaneous interleukin-2, in patients with metastatic renal carcinoma: analysis of 60 cases]
Archivio italiano di urologia, andrologia : organo ufficiale [di] Società italiana di ecografia urologica e nefrologica / Associazione ricerche in urologia 1995;67(2):149-53.
1995: Viganò M G; Lissoni P; Barni S; Tancini G; Scardino E; Favini P; Baccalini A; Verweij F; Strada G; Rocco F
[Lymphocyte levels before treatment with subcutaneous interleukin-2 and during maintenance treatment in relation to the clinical efficacy in metastatic renal carcinoma]
Archivio italiano di urologia, andrologia : organo ufficiale [di] Società italiana di ecografia urologica e nefrologica / Associazione ricerche in urologia 1995;67(2):143-7.
1995: Lissoni P; Barni S; Meregalli S; Fossati V; Cazzaniga M; Esposti D; Tancini G
Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone.
British journal of cancer 1995;71(4):854-6.
1995: Lissoni P; Barni S; Tancini G; Mainini E; Piglia F; Maestroni G J; Lewinski A
Immunoendocrine therapy with low-dose subcutaneous interleukin-2 plus melatonin of locally advanced or metastatic endocrine tumors.
Oncology 1995;52(2):163-6.
1995: Lissoni P; Brivio F; Brivio O; Fumagalli L; Gramazio F; Rossi M; Emanuelli G; Alderi G; Lavorato F
Immune effects of preoperative immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dose interleukin-2 plus the neurohormone melatonin in gastrointestinal tract tumor patients.
Journal of biological regulators and homeostatic agents 1995;9(1):31-3.
1995: Lissoni P; Barni S; Ardizzoia A; Scardino E; Tancini G; Viganò M G
Correlation between pretreatment serum levels of neopterin and response to interleukin-2 immunotherapy in cancer patients.
Journal of biological regulators and homeostatic agents 1995;9(1):21-3.
1995: Paolorossi F; Villa S; Barni S; Tancini G; Andres M; Lissoni P
Second-line therapy with interferon-alpha plus vinblastine in metastatic renal cell cancer patients progressed under interleukin-2 subcutaneous immunotherapy.
Tumori 1995;81(1):45-7.
1995: Lissoni P; Barni S; Tancini G; Ardizzoia A; Tisi E; Angeli M; Rizzi A
Intracavitary therapy of neoplastic effusions with cytokines: comparison among interferon alpha, beta and interleukin-2.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1995;3(1):78-80.
1994: Lissoni P; Meregalli S; Fossati V; Paolorossi F; Barni S; Tancini G; Frigerio F
A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer.
Tumori 1994;80(6):464-7.
1994: Lissoni P; Barni S; Tancini G; Fossati V; Frigerio F
Pineal-opioid system interactions in the control of immunoinflammatory responses.
Annals of the New York Academy of Sciences 1994;741():191-6.
1994: Lissoni P; Barni S; Tancini G; Brivio F; Tisi E; Zubelewicz B; Braczkowski R
Role of the pineal gland in the control of macrophage functions and its possible implication in cancer: a study of interactions between tumor necrosis factor-alpha and the pineal hormone melatonin.
Journal of biological regulators and homeostatic agents 1994;8(4):126-9.
1994: Lissoni P; Barni S; Andres M; Scardino E; Vigoré L; Vezzo R; Rescaldani R; Tancini G
Lymphocytosis decline is not responsible for tumor progression in cancer patients chronically treated with interleukin-2.
Tumori 1994;80(4):283-5.
1994: Lissoni P; Barni S; Cazzaniga M; Ardizzoia A; Rovelli F; Brivio F; Tancini G
Efficacy of the concomitant administration of the pineal hormone melatonin in cancer immunotherapy with low-dose IL-2 in patients with advanced solid tumors who had progressed on IL-2 alone.
Oncology 1994;51(4):344-7.
1994: Brackowski R; Zubelewicz B; Romanowski W; Lissoni P; Barni S; Tancini G; Maestroni G J
Preliminary study on modulation of the biological effects of tumor necrosis factor-alpha in advanced cancer patients by the pineal hormone melatonin.
Journal of biological regulators and homeostatic agents 1994;8(3):77-80.
1994: Barni S; Lissoni P; Brivio F; Fumagalli L; Merlini D; Cataldo M; Rovelli F; Tancini G
Serum levels of insulin-like growth factor-I in operable breast cancer in relation to the main prognostic variables and their perioperative changes in relation to those of prolactin.
Tumori 1994;80(3):212-5.
1994: Lissoni P; Cazzaniga M; Rovelli F; Mainini E; Tancini G; Barni S
Ondansetron does not stimulate prolactin release in breast cancer patients.
Tumori 1994;80(3):209-11.
1994: Lissoni P; Bastone A; Barni S; Tancini G; Galli M A
Normalization of idiopathic arterial hypertension following cancer immunotherapy with interleukin-2.
Journal of biological regulators and homeostatic agents 1994;8(2):65-6.
1994: Lissoni P; Barni S; Ardizzoia A; Fossati V; Paolorossi F; Tancini G
Weekly epirubicin plus low-dose interleukin-2 subcutaneous therapy in breast cancer: preliminary immunobiological results.
Journal of biological regulators and homeostatic agents 1994;8(2):53-5.
1994: Lissoni P; Barni S; Ardizzoia A; Tancini G; Conti A; Maestroni G
A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms.
Cancer 1994;73(3):699-701.
1994: Lissoni P; Barni S; Tancini G; Ardizzoia A; Ricci G; Aldeghi R; Brivio F; Tisi E; Rovelli F; Rescaldani R
A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma.
British journal of cancer 1994;69(1):196-9.
1994: Lissoni P; Barni S; Ardizzoia A; Crispino S; Paolorossi F; Andres M; Scardino E; Tancini G
Prognostic factors of the clinical response to subcutaneous immunotherapy with interleukin-2 alone in patients with metastatic renal cell carcinoma.
Oncology 1994;51(1):59-62.
1994: Lissoni P; Brivio F; Fumagalli L; Galimberti C; Cataldo M; Marsili M T; Brivio O; Barni S; Tancini G; Angelini A
A study of interactions among markers of macrophage functions in metastatic solid tumors: neopterin levels in relation to those of tumor necrosis factor-alpha and of soluble interleukin-2 receptors.
Journal of biological regulators and homeostatic agents 1994;8(1):32-5.
1994: Aldeghi R; Lissoni P; Barni S; Ardizzoia A; Tancini G; Piperno A; Pozzi M; Ricci G; Conti A; Maestroni G J
Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinoma.
European journal of cancer (Oxford, England : 1990) 1994;30A(2):167-70.
1993: Lissoni P; Brivio F; Ardizzoia A; Tancini G; Barni S
Subcutaneous therapy with low-dose interleukin-2 plus the neurohormone melatonin in metastatic gastric cancer patients with low performance status.
Tumori 1993;79(6):401-4.
1993: Lissoni P; Barni S; Ardizzoia A; Andres M; Scardino E; Cardellini P; Della Bitta R; Tancini G
A randomized study of low-dose interleukin-2 subcutaneous immunotherapy versus interleukin-2 plus interferon-alpha as first line therapy for metastatic renal cell carcinoma.
Tumori 1993;79(6):397-400.
1993: Lissoni P; Barni S; Tancini G; Rovelli F; Ardizzoia A; Conti A; Maestroni G J
A study of the mechanisms involved in the immunostimulatory action of the pineal hormone in cancer patients.
Oncology 1993;50(6):399-402.
1993: Ardizzoia A; Lissoni P; Tancini G; Paolorossi F; Crispino S; Villa S; Barni S
Respiratory distress syndrome in patients with advanced cancer treated with pentoxifylline: a randomized study.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1993;1(6):331-3.
1993: Barni S; Lissoni P; Ardizzola A; Vigoré L; Vezzo R; Rescaldani R; Tancini G
Immunotherapy with low-dose subcutaneous interleukin-2 plus beta-interferon as a second-line therapy for metastatic colorectal carcinoma.
Tumori 1993;79(5):343-6.
1993: Lissoni P; Barni S; Ardizzoia A; Olivini G; Brivio F; Tisi E; Tancini G; Characiejus D; Kothari L
Cancer immunotherapy with low-dose interleukin-2 subcutaneous administration: potential efficacy in most solid tumor histotypes by a concomitant treatment with the pineal hormone melatonin.
Journal of biological regulators and homeostatic agents 1993;7(4):121-5.
1993: Lissoni P; Barni S; Tancini G; Brivio F; Cardellini P; Vaghi M; Fossati V; Frigerio F
Immunoendocrine therapy with interleukin-2 (IL-2) and medroxyprogesterone acetate (MPA): a randomized study with or without MPA in metastatic renal cancer patients during IL-2 maintenance treatment after response or stable disease to IL-2 subcutaneous therapy.
Tumori 1993;79(4):246-9.
1993: Crispino S; Lissoni P; Ardizzoia A; Rovelli F; Perego M S; Grassi M G; Barni S; Pittalis S; Tancini G
Effects of granulocyte-macrophage colony stimulating factor on soluble interleukin-2 receptor serum levels and their relation to neopterin and tumor necrosis factor-alpha in cancer patients.
Journal of biological regulators and homeostatic agents 1993;7(3):92-4.
1993: Lissoni P; Barni S; Tancini G; Ardizzoia A; Rovelli F; Cazzaniga M; Brivio F; Piperno A; Aldeghi R; Fossati D
Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract.
British journal of cancer 1993;67(6):1404-7.
1993: Lissoni P; Galli M A; Tancini G; Barni S
Prevention by L-carnitine of interleukin-2 related cardiac toxicity during cancer immunotherapy.
Tumori 1993;79(3):202-4.
1993: Lissoni P; Meregalli S; Fossati V; Barni S; Tancini G; Barigozzi P; Frigerio F
Radioendocrine therapy of brain tumors with the long acting opioid antagonist naltrexone in association with radiotherapy.
Tumori 1993;79(3):198-201.
1993: Lissoni P; Barni S; Tancini G; Andres M; Scardino E; Cardellini P; Frascaroli M; Ardizzoia A; Crispino S; Vicini D
[Immunotherapy with low-dose subcutaneous interleukin-2 in metastatic renal carcinoma]
Archivio italiano di urologia, andrologia : organo ufficiale [di] Società italiana di ecografia urologica e nefrologica / Associazione ricerche in urologia 1993;65(2):123-8.
1993: Brivio F; Lissoni P; Redaelli R; Maggioni A; Rovelli F; Rescaldani R; Borin F; Erba L; Alderi G
Influence of blood transfusions on surgery-induced immune changes in colorectal carcinoma.
Minerva chirurgica 1993;48(7):331-5.
1993: Lissoni P; Ardizzoia A; Perego M S; Grassi M G; Arosio M; D'Amico P; Cazzaniga M; Crispino S; Tancini G; Barni S
Inhibition of tumor necrosis factor-alpha secretion by pentoxifylline in advanced cancer patients with abnormally high blood levels of tumor necrosis factor-alpha.
Journal of biological regulators and homeostatic agents 1993;7(2):73-5.
1993: Lissoni P; Pittalis S; Brivio F; Tisi E; Rovelli F; Ardizzoia A; Barni S; Tancini G; Giudici G; Biondi A
In vitro modulatory effects of interleukin-3 on macrophage activation induced by interleukin-2.
Cancer 1993;71(6):2076-81.
1993: Barni S; Archili C; Lissoni P; Paolorossi F; Crispino S; Tancini G
A weekly schedule of epirubicin in pretreated advanced breast cancer.
Tumori 1993;79(1):45-8.
1993: Lissoni P; Ardizzoia A; Tisi E; Rossini F; Barni S; Tancini G; Conti A; Maestroni G J
Amplification of eosinophilia by melatonin during the immunotherapy of cancer with interleukin-2.
Journal of biological regulators and homeostatic agents 1993;7(1):34-6.
1993: Lissoni P; Cazzaniga M; Ardizzoia A; Rossini F; Fiorelli G; Tancini G; Pittalis S; Barni S
Cytokine regulation of iron metabolism: effect of low-dose interleukin-2 subcutaneous therapy on ferritin, transferrin and iron blood concentrations in cancer patients.
Journal of biological regulators and homeostatic agents 1993;7(1):31-3.
1993: Brivio F; Lissoni P; Barni S; Tancini G; Ardizzoia A; Erba L; Alderi G; Nociti V
Effects of a preoperative course of interleukin-2 on surgical and immunobiological variables in patients with colorectal cancer: a phase 2 study.
The European journal of surgery = Acta chirurgica 1993;159(1):43-7.
1993: Lissoni P; Barni S; Rovelli F; Brivio F; Ardizzoia A; Tancini G; Conti A; Maestroni G J
Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: preliminary results.
European journal of cancer (Oxford, England : 1990) 1993;29A(2):185-9.
1993: Lissoni P; Barni S; Tisi E; Rovelli F; Pittalis S; Rescaldani R; Vigoré L; Biondi A; Ardizzoia A; Tancini G
In vivo biological results of the association between interleukin-2 and interleukin-3 in the immunotherapy of cancer.
European journal of cancer (Oxford, England : 1990) 1993;29A(8):1127-32.
1992: Barni S; Lissoni P; Cazzaniga M; Ardizzoia A; Paolorossi F; Brivio F; Perego M; Tancini G; Conti A; Maestroni G
Neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin as a second-line treatment in metastatic colorectal carcinoma.
Tumori 1992;78(6):383-7.
1992: Lissoni P; Rovelli F; Barni S; Ardizzoia A; Pittalis S; Tisi E; Perlangeli V; Tancini G
Modulation of macrophage response to interleukin-2 immunotherapy by interleukin-3 in cancer patients.
Biological chemistry Hoppe-Seyler 1992;373(12):1217-22.
1992: Lissoni P; Mainini E; Rovelli F; Mazzi C; Ardizzoia A; Gelosa M; Capra M; Rivolta M R
A clinical study of the pineal hormone melatonin in patients with growth hormone or prolactin secreting pituitary tumours.
The European journal of medicine 1992;1(7):407-10.
1992: Lissoni P; Ardizzoia A; Rovelli F; Perego M; Cardellini P; Tancini G; Barni S
Effect of interferon-alpha on soluble interleukin-2 receptor and tumor necrosis factor increase during immunotherapy with interleukin-2.
The International journal of biological markers 1992;7(4):268-9.
1992: Lissoni P; Rovelli F; Tancini G; Tisi E; Rivolta M R; Ardizzoia A; Brivio F
Inhibitory effect of interleukin-3 on interleukin-2-induced cortisol release in the immunotherapy of cancer.
Journal of biological regulators and homeostatic agents 1992;6(4):113-5.
1992: Lissoni P; Rovelli F; Tisi E; Ballabio D; Benenti C; Ardizzoia A; Barni S; Tancini B
Effects of interleukin-2 immunotherapy on soluble lymphocyte markers in cancer patients.
The International journal of biological markers 1992;7(4):260-2.
1992: Lissoni P; Rovelli F; Tisi E; Ardizzoia A; Perlangeli V; Barni S; Tancini G
Endocrine effects of human recombinant interleukin-3 in cancer patients.
The International journal of biological markers 1992;7(4):230-3.
1992: Crispino S; Lissoni P; Ardizzoia A; Barni S; Rovelli F; Tancini G
Effects of granulocyte-macrophage colony stimulating factor on cortisol, growth hormone, prolactin and melatonin in cancer patients (short communication).
Journal of biological regulators and homeostatic agents 1992;6(4):142-4.
1992: Lissoni P; Barni S; Ardizzoia A; Brivio F; Tancini G; Conti A; Maestroni G J
Immunological effects of a single evening subcutaneous injection of low-dose interleukin-2 in association with the pineal hormone melatonin in advanced cancer patients.
Journal of biological regulators and homeostatic agents 1992;6(4):132-6.
1992: Lissoni P; Pelizzoni F; Mauri O; Perego M; Pittalis S; Barni S
Enhanced secretion of tumour necrosis factor in patients with myocardial infarction.
The European journal of medicine 1992;1(5):277-80.
1992: Ardizzoia A; Lissoni P; Brivio F; Tisi E; Perego M S; Grassi M G; Pittalis S; Crispino S; Barni S; Tancini G
Tumor necrosis factor in solid tumors: increased blood levels in the metastatic disease.
Journal of biological regulators and homeostatic agents 1992;6(3):103-7.
1992: Lissoni P; Tisi E; Barni S; Ardizzoia A; Rovelli F; Rescaldani R; Ballabio D; Benenti C; Angeli M; Tancini G
Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer.
British journal of cancer 1992;66(1):155-8.
1992: Tisi E; Lissoni P; Angeli M; Arrigoni C; Corno E; Cassina E; Ballabio D; Benenti C; Barni S; Tancini G
Postoperative increase in soluble interleukin-2 receptor serum levels as predictor for early recurrence in non-small cell lung carcinoma.
Cancer 1992;69(10):2458-62.
1992: Lissoni P; Barni S; Ardizzoia A; Paolorossi F; Tisi E; Crispino S; Tancini G
Intracavitary administration of interleukin-2 as palliative therapy for neoplastic effusions.
Tumori 1992;78(2):118-20.
1992: Tisi E; Cassina E; Ballabio D; Benenti C; Perego M; Barni S; Tancini G; Lissoni P
Blood levels of atrial natriuretic peptide in non-small cell lung cancer and their changes with surgery.
The International journal of biological markers 1992;7(2):121-2.
1992: Lissoni P; Barni S; Ardizzoia A; Crispino S; Paolorossi F; Archili C; Vaghi M; Tancini G
Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alpha.
European journal of cancer (Oxford, England : 1990) 1992;28(1):92-6.
1992: Brivio F; Lissoni P; Tisi E; Erba L; Barni S; Tancini G; Rescaldani R; Alderi G; Nociti V
Effects of a preoperative therapy with interleukin-2 on surgery-induced lymphocytopenia in cancer patients.
Oncology 1992;49(3):215-8.
1992: Lissoni P; Barni S; Ardizzoia A; Paolorossi F; Crispino S; Tancini G; Tisi E; Archili C; De Toma D; Pipino G
Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin.
Oncology 1992;49(5):336-9.
1991: Lissoni P; Brivio F; Pittalis S; Perego M S; Ardizzoia A; Mauri O; Barni S; Crispino S; Tancini G
Decrease in cholesterol levels during the immunotherapy of cancer with interleukin-2.
British journal of cancer 1991;64(5):956-8.
1991: Lissoni P; Barni S; Mauri O; Pelizzoni F; Pittalis S; Osculati G; Valagussa F
[Cardioangioimmunology: the immune implications in the principle cardiovascular pathologies]
Giornale italiano di cardiologia 1991;21(10):1139-46.
1991: Barni S; Lissoni P; Paolorossi F; Rescaldani R; Crispino S; Archili C; Cattaneo G; Tancini G
Mitoxantrone as a single agent in pretreated metastatic breast cancer: effects on T lymphocyte subsets and their relation to clinical response.
Tumori 1991;77(3):227-31.
1991: Lissoni P; Barni S; Rovelli F; Crispino S; Fumagalli G; Pescia S; Vaghi M; Camesasca G; Tancini G
Neuroendocrine effects of subcutaneous interleukin-2 injection in cancer patients.
Tumori 1991;77(3):212-5.
1991: Barni S; Lissoni P; Mandelli D; Archili C; Real G; Sormani A L; Caprotti R; Tancini G
Relation between surgery-induced prolactin increase and the menstrual cycle phase at time of surgery in premenopausal breast cancer.
The International journal of biological markers 1991;6(2):103-6.
1991: Brivio F; Lissoni P; Mancini D; Tisi E; Tancini G; Barni S; Nociti V
Effect of antitumor surgery on soluble interleukin-2 receptor serum levels.
American journal of surgery 1991;161(4):466-9.
1991: Tisi E; Lissoni P; Rovelli F; Mandelli D; Barni S; Tancini G
Blood levels of IGF-I in non-small cell lung cancer: relation to clinical data.
The International journal of biological markers 1991;6(2):99-102.
1991: Lissoni P; Barni S; Rovelli F; Tancini G
Lower survival in metastatic cancer patients with reduced interleukin-2 blood concentrations. Preliminary report.
Oncology 1991;48(2):125-7.
1991: Lissoni P; Tisi E; Brivio F; Barni S; Rovelli F; Perego M; Tancini G
Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2.
European journal of cancer (Oxford, England : 1990) 1991;27(8):1014-6.
1991: Lissoni P; Barni S; Cattaneo G; Tancini G; Esposti G; Esposti D; Fraschini F
Clinical results with the pineal hormone melatonin in advanced cancer resistant to standard antitumor therapies.
Oncology 1991;48(6):448-50.
1990: Lissoni P; Barni S; Cattaneo G; Archili C; Perego M; Tancini G
Evaluation of the cardiovascular toxicity related to cancer immunotherapy with interleukin-2 by monitoring atrial natriuretic peptide secretion: a case report.
Tumori 1990;76(6):603-5.
1990: Lissoni P; Brivio F; Barni S; Tancini G; Cattaneo G; Archili C; Conti A; Maestroni G J
Neuroimmunotherapy of human cancer with interleukin-2 and the neurohormone melatonin: its efficacy in preventing hypotension.
Anticancer research 1990;10(6):1759-61.
1990: Colombo A; Crispino S; Tancini G; Personeni A; Taino R; Sarti E; Barni S; Lissoni P; Placa F; Mazzola P
[Radiotherapy plus a combination of cisplatin and 5-fluorouracil for locally advanced head and neck neoplasms. Study of feasibility and preliminary results]
La Radiologia medica 1990;80(5):713-8.
1990: Lissoni P; Tancini G; Rovelli F; Cattaneo G; Archili C; Barni S
Serum interleukin-2 levels in relation to the neuroendocrine status in cancer patients.
British journal of cancer 1990;62(5):838-9.
1990: Lissoni P; Pelizzoni F; Grugni G; Guzzaloni G; Mauri O; Archili C; Galli M A; Morabito F
Melatonin response to atrial natriuretic peptide administration in healthy volunteers.
Journal of cardiovascular pharmacology 1990;16(5):850-2.
1990: Lissoni P; Barni S; Cattaneo G; Archili C; Crispino S; Tancini G; D'Angelo L; Magni S; Fiorelli G
Activation of the complement system during immunotherapy of cancer with interleukin-2: a possible explanation of the capillary leak syndrome.
The International journal of biological markers 1990;5(4):195-7.
1990: Lissoni P; Galli M A; Barni S; Colombo V; Pelizzoni F; Fumagalli R; Tancini G
[The cardiovascular toxicity of interleukin-2: the pathogenic mechanisms and treatment]
Giornale italiano di cardiologia 1990;20(7):631-5.
1990: Lissoni P; Barni S; Archili C; Cattaneo G; Rovelli F; Conti A; Maestroni G J; Tancini G
Endocrine effects of a 24-hour intravenous infusion of interleukin-2 in the immunotherapy of cancer.
Anticancer research 1990;10(3):753-7.
1990: Lissoni P; Mainini E; Mazzi C; Cattaneo G; Barni S
A study of pineal-prolactin interaction: prolactin response to an acute melatonin injection in patients with hyperprolactinemia.
Journal of endocrinological investigation 1990;13(2):85-9.
1990: Barni S; Lissoni P; Paolorossi F; Crispino S; Archili C; Tancini G
A study of the pineal hormone melatonin as a second line therapy in metastatic colorectal cancer resistant to fluorouracil plus folates.
Tumori 1990;76(1):58-60.
1990: Lissoni P; Barni S; Rovelli F; Rescaldani R; Rizzo V; Biondi A; Tancini G
Correlation of serum interleukin-2 levels, soluble interleukin-2 receptors and T lymphocyte subsets in cancer patients.
Tumori 1990;76(1):14-7.
1990: Archili C; Lissoni P; Cattaneo G; Rovelli F; Brivio F; Tancini G; Barni S
Lack of changes in soluble interleukin-2 receptor serum levels during chemotherapy-induced lymphocyte damage.
The International journal of biological markers 1990;5(1):43-5.
1990: Lissoni P; Barni S; Rovelli F; Viviani S; Maestroni G J; Conti A; Tancini G
The biological significance of soluble interleukin-2 receptors in solid tumors.
European journal of cancer (Oxford, England : 1990) 1990;26(1):33-6.
1990: Viviani S; Negretti E; Orazi A; Sozzi G; Santoro A; Lissoni P; Esposti G; Fraschini F
Preliminary studies on melatonin in the treatment of myelodysplastic syndromes following cancer chemotherapy.
Journal of pineal research 1990;8(4):347-54.
1990: Lissoni P; Crispino S; Barni S; Sormani A; Brivio F; Pelizzoni F; Brenna A; Bratina G; Tancini G
Pineal gland and tumor cell kinetics: serum levels of melatonin in relation to Ki-67 labeling rate in breast cancer.
Oncology 1990;47(3):275-7.
1990: Lissoni P; Pelizzoni F; Perego M; Fondrini G; Grugni G; Guzzaloni G; Morabito F
A study of heart-pineal interactions: atrial natriuretic peptide response to melatonin administration in healthy humans.
Journal of pineal research 1990;9(3):167-70.
1990: Lissoni P; Sormani A L; Tancini G; Cattaneo G; Archili C; Mandelli D; Crispino S; Paolorossi F; Barni S
Postoperative hyperprolactinaemia and early recurrence rate in breast cancer.
European journal of cancer (Oxford, England : 1990) 1990;26(9):953-6.
1990: Tancini G; Barni S; Rescaldani R; Fiorelli G; Vivani S; Lissoni P
Analysis of T helper and suppressor lymphocyte subsets in relation to the clinical stage of solid neoplasms.
Oncology 1990;47(5):381-4.
1990: Lissoni P; Tancini G; Archili C; Rescaldani R; Cattaneo G; Crispino S; Barni S
Changes in T lymphocyte subsets after single dose epirubicin.
European journal of cancer (Oxford, England : 1990) 1990;26(6):767-8.
1989: Crispino S; Brenna A; Colombo D; Flores B; D'Amico S; Lissoni P; Barni S; Paolorossi F; Bratina G; Tancini G
Ki-67 labeling index in breast cancer.
Tumori 1989;75(6):557-62.
1989: Lissoni P; Barni S; Rescaldani R; Rovelli F; Tancini G
Serum levels of soluble interleukin-2 receptors and their relation to lymphocyte subpopulations in patients with metastatic solid tumours.
British journal of cancer 1989;60(4):616-7.
1989: Lissoni P; Viviani S; Santoro A; Barni S; Tancini G
Serum levels of interleukin-2 in cancer patients: preliminary considerations.
The International journal of biological markers 1989;4(4):203-6.
1989: Crispino S; Tancini G; Barni S; Lissoni P
Evidence for altered hypothalamic-hypophyseal-gonadal axis in untreated patients with testicular germ-cell tumor.
Tumori 1989;75(5):505-9.
1989: Lissoni P; Tancini G; Barni S; Viviani S; Archili C; Cattaneo G; Fiorelli G
Alterations of pineal gland and of T lymphocyte subsets in metastatic cancer patients: preliminary results.
Journal of biological regulators and homeostatic agents 1989;3(4):181-3.
1989: Lissoni P; Rizzo V; Barni S; Rescaldani R; Rovelli F; Biondi A; Archili C; Frigerio F; Tancini G
Interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors in patients with solid tumors are not correlated.
The International journal of biological markers 1989;4(3):170-3.
1989: Barni S; Lissoni P; Sormani A; Pelizzoni F; Brivio F; Crispino S; Tancini G
The pineal gland and breast cancer: serum levels of melatonin in patients with mammary tumors and their relation to clinical characteristics.
The International journal of biological markers 1989;4(3):157-62.
1989: Lissoni P; Barni S; Tancini G; Viviani S; Rovelli F; Rescaldani R; Fiorelli G
Effects of cancer chemotherapy on the relation between serum levels of soluble interleukin-2 receptors and CD4/CD8 ratio in patients with solid neoplasms.
Journal of biological regulators and homeostatic agents 1989;3(3):131-3.
1989: Tagliabue M; Lissoni P; Barni S; Macchi I; Tancini G; Crispino S; Ferri L; Salvini E
A radiologic study by CT scan of pineal size in cancer patients: correlation to melatonin blood levels.
Tumori 1989;75(3):226-8.
1989: Lissoni P; Barni S; Crispino S; Tancini G; Fraschini F
Endocrine and immune effects of melatonin therapy in metastatic cancer patients.
European journal of cancer & clinical oncology 1989;25(5):789-95.
1989: Tancini G; Lissoni P; Barni S; Rescaldani R; Rovelli F; Sormani A; Crispino S; Saporito T; Tisi E; Benenti C
Serum levels of soluble interleukin-2 receptors and their relation to CD4/CD8 ratio in patients with advanced solid tumors.
The International journal of biological markers 1989;4(2):123-4.
1989: Tancini G; Barni S; Crispino S; Paolorossi F; Lissoni P
A study of thyroid function in cancer cachexia.
Tumori 1989;75(2):185-8.
1989: Crispino S; Lombardi G; Bratina G; Lissoni P; Barni S; Tancini G
Malignant testicular germ cell tumor in father and son: a case report.
Tumori 1989;75(2):177-80.
1989: Lissoni P; Barni S; Garuti F; Astuti R; Tancini G
Opioid receptors in human neoplasms: growth hormone and prolactin response to morphine, met-enkephalin and buprenorphine in cancer patients.
The International journal of biological markers 1989;4(1):55-6.
1989: Lissoni P; Crispino S; Barni S; Tancini G
Prolactin secretion in testicular cancer patients.
The International journal of biological markers 1989;4(1):27-30.
1988: Rovelli F; Lissoni P; Crispino S; Barni S; Fumagalli G; Paolorossi F; Tancini G
Increased level of soluble interleukin-2 receptor in advanced solid tumors: a preliminary study.
Tumori 1988;74(6):633-7.
1988: Esposti D; Lissoni P; Tancini G; Barni S; Crispino S; Paolorossi F; Rovelli F; Ferri L; Cattaneo G; Esposti G
A study on the relationship between the pineal gland and the opioid system in patients with cancer. Preliminary considerations.
Cancer 1988;62(3):494-9.
1988: Barni S; Lissoni P; Crispino S; Rovelli F; Esposti G; Fraschini F; Tancini G
Serum levels of melatonin in cancer patients and their relation to body sizes.
The International journal of biological markers 1988;3(3):193-6.
1988: Lissoni P; Tancini G; Barni S; Crispino S; Paolorossi F; Rovelli F; Cattaneo G; Fraschini F
Melatonin increase as predictor for tumor objective response to chemotherapy in advanced cancer patients.
Tumori 1988;74(3):339-45.
1988: Barni S; Lissoni P; Rovelli F; Crispino S; Paolorossi F; Esposti D; Esposti G; Fraschini F; Tancini G
Alteration of opioid peptide circadian rhythm in cancer patients.
Tumori 1988;74(3):357-60.
1988: Lissoni P; Barni S; Crispino S; Cattaneo G; Tancini G
Endocrine and clinical effects of an LHRH analogue in pretreated advanced breast cancer.
Tumori 1988;74(3):303-8.
1988: Barni S; Lissoni P; Crispino S; Cattaneo G; Rovelli F; Fumagalli G; Tancini G
Neuroimmunomodulation in cancer patients: correlations between melatonin and beta-endorphin blood levels and T helper/suppressor ratio.
The International journal of biological markers 1988;3(2):82-6.
1988: Esposti D; Lissoni P; Mauri R; Rovelli F; Orsenigo L; Pescia S; Vegetti G; Esposti G; Fraschini F
The pineal gland-opioid system relation: melatonin-naloxone interactions in regulating GH and LH releases in man.
Journal of endocrinological investigation 1988;11(2):103-6.
1988: Lissoni P; Barni S; Tancini G; Crispino S; Paolorossi F; Cattaneo G; Lucini V; Mariani M; Esposti D; Esposti G
Relation between lymphocyte subpopulations and pineal function in patients with early or metastatic cancer.
Annals of the New York Academy of Sciences 1988;521():290-9.
1988: Esposti D; Esposti G; Lissoni P; Parravicini L; Fraschini F
Action of morphine on melatonin release in the rat.
Journal of pineal research 1988;5(1):35-9.
1987: Lissoni P; Barni S; Paolorossi F; Crispino S; Rovelli F; Ferri L; Delitala G; Tancini G
Evidence for altered opioid activity in patients with cancer.
British journal of cancer 1987;56(6):834-7.
1987: Lissoni P; Barni S; Tancini G; Crispino S; Paolorossi F; Lucini V; Mariani M; Cattaneo G; Esposti D; Esposti G
Clinical study of melatonin in untreatable advanced cancer patients.
Tumori 1987;73(5):475-80.
1987: Colombo A; Crispino S; Barni S; Paolorossi F; Frigerio F; Tancini G; Lissoni P; Placa F; Mazzola P; Nava S
[Concomitant therapy with cisplatin and radiotherapy in locally advanced tumors of the cervico-facial area]
La Radiologia medica 1987;74(4):334-7.
1987: Barni S; Frigerio F; Lissoni P; Crispino S; Paolorossi F
Anal squamous cell carcinoma arising on radio-dermatitis cured with chemotherapy alone: case report.
Tumori 1987;73(4):423-4.
1987: Barni S; Lissoni P; Paolorossi F; Crispino S; Rovelli F; Ferri L; Sormani A; D'Alonso U; Bugatti A; Nociti V
Effects of radical mastectomy on prolactin blood levels in patients with breast cancer.
European journal of cancer & clinical oncology 1987;23(8):1141-5.
1987: Lissoni P; Bastone A; Sala R; Mauri R; Rovelli F; Viviani S; Bajetta E; Esposti D; Esposti G; di Bella L
The clinical significance of melatonin serum determination in oncological patients and its correlations with GH and PRL blood levels.
European journal of cancer & clinical oncology 1987;23(7):949-57.
1987: Lissoni P; Paolorossi F; Barni S; Tancini G; Crispino S; Rovelli F; Ferri L; Esposti G; Esposti D; Fraschini F
Correlation between changes in prolactin and melatonin serum levels after radical mastectomy.
Tumori 1987;73(3):263-7.
1987: Lissoni P; Barni S; Crispino S; Tancini G; Paolorossi F; Ferri L; Delitala G
Synthetic enkephalin analog in the treatment of cancer chemotherapy-induced vomiting.
Cancer treatment reports 1987;71(6):665-6.
1987: Barni S; Lissoni P; Tancini G; Crispino S; Paolorossi F; Rovelli F; Fumagalli G; Ferri L; Esposti D; Esposti G
Acute effects of various chemotherapeutic combinations on hypophyseal and pineal hormone secretions in cancer patients.
Tumori 1987;73(2):181-5.
1986: Barni S; Lissoni P; Tancini G; Crispino S; Paolorossi F; Rovelli F; Fumagalli G; Ferri L
Prolactin response to thyrotropin-releasing hormone in early and advanced human breast cancer.
Tumori 1986;72(4):399-403.
1986: Lissoni P; Resentini M; Mauri R; Fraschini F; Morabito F
[Levels of melatonin in prepubertal and pubertal subjects during different seasons of the year]
Minerva pediatrica 1986;38(11-12):471-6.
1986: Lissoni P; Viviani S; Bajetta E; Buzzoni R; Barreca A; Mauri R; Resentini M; Morabito F; Esposti D; Esposti G
A clinical study of the pineal gland activity in oncologic patients.
Cancer 1986;57(4):837-42.
1986: Lissoni P; Esposti D; Esposti G; Mauri R; Resentini M; Morabito F; Fumagalli P; Santagostino A; Delitala G; Fraschini F
A clinical study on the relationship between the pineal gland and the opioid system.
Journal of neural transmission 1986;65(1):63-73.
1985: Mauri R; Lissoni P; Resentini M; De Medici C; Morabito F; Djemal S; Di Bella L; Fraschini F
Effects of melatonin on PRL secretion during different photoperiods of the day in prepubertal and pubertal healthy subjects.
Journal of endocrinological investigation 1985;8(4):337-41.
1984: Mauri R; Resentini M; Lissoni P; Morabito F
[Prolactin response to TRH in patients with idiopathic delayed puberty]
Minerva pediatrica 1984;36(20):1013-6.
1982: Resentini M; Canto G; Lacqua P; Lissoni P; Mauri R; Marincola G; Morabito F
[The lipid profile and nephelometry in obesity in children and juveniles]
Minerva pediatrica 1982;34(20):861-70.

Sign-in to see more